Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension
